Screener
Acadia Pharmaceuticals ACAD Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
FAQ
- What is Acadia Pharmaceuticals's accounts receivable?
- Acadia Pharmaceuticals (ACAD) reported accounts receivable of $150.64M in Q2 2026.
- How has Acadia Pharmaceuticals's accounts receivable changed year-over-year?
- Acadia Pharmaceuticals's accounts receivable increased by 40.1% year-over-year, from $107.51M to $150.64M.
- What is the long-term trend for Acadia Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's accounts receivable has grown at a 20.3% compound annual growth rate (CAGR), from $48.25M to $121.46M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Acadia Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude